Get the Stockscreener App
1.32
1.91%
0.01
After Hours:
1.32
Medicinova Inc stock is traded at $1.32, with a volume of 67,356.
It is up +1.91% in the last 24 hours and down -1.11% over the past month.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
See More
Previous Close:
$1.31
Open:
$1.32
24h Volume:
67,356
Relative Volume:
1.52
Market Cap:
$64.97M
Revenue:
$596.60K
Net Income/Loss:
$-11.72M
P/E Ratio:
-5.5323
EPS:
-0.2386
Net Cash Flow:
$-9.51M
1W Performance:
+1.14%
1M Performance:
-1.11%
6M Performance:
-16.56%
1Y Performance:
+1.91%
1-Day Range:
$1.3011
$1.34
1-Week Range:
$1.3001
$1.4386
52-Week Range:
$1.168
$1.96
Medicinova Inc Stock (MNOV) Company Profile
Name
Medicinova Inc
Sector
Industry
Phone
858-373-1500
Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.32 | 64.48M | 596.60K | -11.72M | -9.51M | -0.2386 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Initiated | H.C. Wainwright | Buy |
| Mar-10-21 | Initiated | Maxim Group | Buy |
| Mar-25-19 | Resumed | B. Riley FBR | Buy |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-18-17 | Initiated | Credit Suisse | Outperform |
| Jan-04-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-24-12 | Downgrade | MLV & Co | Buy → Hold |
| Oct-18-11 | Reiterated | MLV Capital | Buy |
| Jun-22-11 | Initiated | Global Hunter Securities | Buy |
| May-12-10 | Initiated | Wedbush | Outperform |
| Nov-12-08 | Reiterated | Ladenburg Thalmann | Buy |
| May-15-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jul-09-07 | Initiated | Punk, Ziegel & Co | Buy |
View All
Medicinova Inc Stock (MNOV) Latest News
FY2028 EPS Estimates for MediciNova Lowered by HC Wainwright - MarketBeat
MediciNova Inc (NASDAQ: MNOV) Share Price, MNOV Stock News, MNOV Share Price & Updates - Kalkine
MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
MediciNova (NASDAQ:MNOV) Announces Quarterly Earnings Results - MarketBeat
MediciNova Inc reports results for the quarter ended June 30Earnings Summary - TradingView
MediciNova: Q2 Earnings Snapshot - AOL.com
MNOV: Q2 2026 revenue grew and net loss narrowed, with cash reserves supporting operations into 2027 - TradingView
MNOV Q2'26 Earnings: EPS estimate is (0.06) USD - TradingView
MediciNova Inc (MNOV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MediciNova Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
MNOV Q2'26 Earnings: revenue estimate is 75.00K USD - TradingView
MediciNova (MNOV) Projected to Release Earnings on Thursday - MarketBeat
Price to book forward of MediciNova, Inc. – NASDAQ:MNOV - tradingview.com
MediciNova, Inc. Revenue Breakdown – NASDAQ:MNOV - TradingView
MediciNova Inc (MNOV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MediciNova Inc (MNOV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MediciNova Inc (MNOV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
MediciNova Inc (MNOV) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
MediciNova Inc (MNOV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to EBIT forward of MediciNova, Inc. – NASDAQ:MNOV - TradingView
Price to sales forward of MediciNova, Inc. – NASDAQ:MNOV - TradingView
Enterprise value to EBIT forward of MediciNova, Inc. – TSE:4875 - TradingView
MediciNova stock trades steady as investors weigh recent losses and pipeline progress - Ad-hoc-news.de
Price to sales forward of MediciNova, Inc. – TSE:4875 - TradingView
MediciNova stock trades steady as pipeline progress contrasts with lower recent revenues - Ad-hoc-news.de
Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Legend Biotech (LEGN) and AngioDynamics (ANGO) - The Globe and Mail
MediciNova, Inc. (NASDAQ:MNOV) Sees Significant Increase in Short Interest - MarketBeat
H.C. Wainwright Maintains MediciNova(MNOV.US) With Buy Rating, Maintains Target Price $10 - Moomoo
MediciNova reaches 200-patient enrollment in ALS study - Investing.com
MediciNova reaches 200-patient enrollment in ALS study By Investing.com - Investing.com Nigeria
ALS patients ineligible for trials join MediciNova's 200-person study - Stock Titan
MNOV Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Progress ContinuesOperating Income Trends - DonanımHaber
D Boral Capital maintains MediciNova (MNOV) buy recommendation - MSN
MediciNova Inc outlines its biotech pipeline as investors watch MN-166 progress - Ad-hoc-news.de
Medicinova Inc (MNOV) Holds Steady Near Support After Modest AdvanceFactor Crowding - dars.gov.et
Medicinova Inc (MNOV) Surges 7.6% as Biotech Stock Tests Resistance at $1.49Opening Range Breakout - dars.gov.et
Enterprise value to revenue forward of MediciNova, Inc. – TSE:4875 - TradingView
Price to earnings forward of MediciNova, Inc. – TSE:4875 - TradingView
Enterprise value to EBITDA forward of MediciNova, Inc. – NASDAQ:MNOV - TradingView
MediciNova completes patient visits in phase 2 NAFLD trial - Investing.com
MediciNova CEO Provides Shareholder Update - GlobeNewswire
Medicinova Inc (MNOV) Edges Higher: Biotech Stock Tests Resistance After Modest GainPrice Target - dars.gov.et
Medicinova Inc (MNOV) Edges Higher as Stock Holds Above Key SupportIV Spike - dars.gov.et
Medicinova Inc (MNOV) Edges Higher, Holds Above Key Support Amid Low-Volume TradeBPI Reversal - dars.gov.et
MNOV Q1 2026 Earnings: EPS Beat Drives Positive Stock Reaction Despite No RevenueQuarterly Profit Report - dars.gov.et
MediciNova, Inc. Actuals & Estimates (NASDAQ:MNOV) - TradingView
Form 4 MediciNova Inc For: 25 June By Investing.com - Investing.com Nigeria
MediciNova (MNOV) director awarded 44,500 stock options - Stock Titan
MediciNova (MNOV) director Nicole Lemerond receives 44,500 stock options grant - Stock Titan
Medicinova Inc Stock (MNOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):